Icecure Medical Ltd ICCM

NAS: ICCM | ISIN: IL0011224156   17/05/2024
1,040 USD (+1,96%)
(+1,96%)   17/05/2024

7 mei 2024 · Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally · Persbericht

15 april 2024 · IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer · Persbericht

3 april 2024 · IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance · Persbericht

2 april 2024 · IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes · Persbericht

27 maart 2024 · IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 · Persbericht

19 maart 2024 · IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy · Persbericht

12 maart 2024 · IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes · Persbericht

7 maart 2024 · IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference · Persbericht

4 maart 2024 · IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 · Persbericht

27 februari 2024 · Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop · Persbericht

26 februari 2024 · Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer · Persbericht

15 februari 2024 · IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan · Persbericht

30 januari 2024 · U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer · Persbericht

29 januari 2024 · IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class · Persbericht

16 januari 2024 · IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation · Persbericht

10 januari 2024 · IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results · Persbericht

3 januari 2024 · New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response · Persbericht

13 december 2023 · Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients" · Persbericht

8 november 2023 · IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023 · Persbericht

6 november 2023 · Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System · Persbericht

Mijn selecties